Pradeep J. Nathan
Research Subjects
Research Interests
Pradeep J. Nathan has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Edward Thomas Bullmore
Department of Psychiatry, University of Cambridge
6 shared publications Annelize Koch
Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom
4 shared publicationsAntonella Napolitano
Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom
3 shared publications- Duncan Richards
Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK
3 shared publications Kay Maltby
Clinical Unit Cambridge, GlaxoSmithKline, Cambridge, United Kingdom
3 shared publicationsWenli X. Tao
Discovery Biometrics, GlaxoSmithKline, Research Triangle Park, North Carolina
3 shared publications
Latest Publications
- 1 April 2013
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 10 (3) , 240-251
The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H3 receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study we examined the safety, tolerability, pharmacokinetics and pro-cognitive effects of GSK239512 (oral) in patients with mild to moderate Alzheimer’s disease using ascending dose titration regimens. Methods: The study was conducted in two parts. Part A was a single-blind, placebo run-in, flexible dose titration over 9 days in two cohorts, each consisting of two patients. Part B was a double-blind, randomised, placebo controlled, parallel group, which investigated 3 flexible dose titration regimens over 4 weeks in 3 cohorts, each consisting of eight patients. Results: Overall, the 5/10/20/40μg and 10/20/40/80μg regimens were well-tolerated. The regimen of 20/40/80/150μg showed the poorest tolerability likely due to the higher starting dose. There were no clinically significant abnormalities in haematology, clinical chemistry, urinalysis parameters and cardiovascular parameters. GSK239512 had positive effects on tasks of attention and memory with effect sizes between 0.56 and 1.37. Conclusions: GSK239512 displayed asatisfactory level of tolerability in patients with Alzheimer’s disease with evidence for positive effects on attention and memory. The findings suggest that a titration regimen with a starting dose of 5-10μg and a maximum dose of 80μg is likely to be a well-tolerated and potentially efficacious regimen for future clinical trials in patients with Alzheimer’s disease. These findings await replication in a larger study.
- 1 April 2013
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 10 (3) , 240-251
The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H3 receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study we examined the safety, tolerability, pharmacokinetics and pro-cognitive effects of GSK239512 (oral) in patients with mild to moderate Alzheimer’s disease using ascending dose titration regimens. Methods: The study was conducted in two parts. Part A was a single-blind, placebo run-in, flexible dose titration over 9 days in two cohorts, each consisting of two patients. Part B was a double-blind, randomised, placebo controlled, parallel group, which investigated 3 flexible dose titration regimens over 4 weeks in 3 cohorts, each consisting of eight patients. Results: Overall, the 5/10/20/40μg and 10/20/40/80μg regimens were well-tolerated. The regimen of 20/40/80/150μg showed the poorest tolerability likely due to the higher starting dose. There were no clinically significant abnormalities in haematology, clinical chemistry, urinalysis parameters and cardiovascular parameters. GSK239512 had positive effects on tasks of attention and memory with effect sizes between 0.56 and 1.37. Conclusions: GSK239512 displayed asatisfactory level of tolerability in patients with Alzheimer’s disease with evidence for positive effects on attention and memory. The findings suggest that a titration regimen with a starting dose of 5-10μg and a maximum dose of 80μg is likely to be a well-tolerated and potentially efficacious regimen for future clinical trials in patients with Alzheimer’s disease. These findings await replication in a larger study.
- 1 October 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (10) , 1456-1467
Multiple‐Dose Safety, Pharmacokinetics, and Pharmacodynamics of the μ‐Opioid Receptor Inverse Agonist GSK1521498
The endogenous opioid system and μ‐opioid receptors in particular have been demonstrated to play a fundamental role in hedonic and motivational behaviors reinforced by rewards. In healthy participants, the authors examined the multiple‐dose safety, pharmacokinetic, and secondary pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being developed for treatment of disorders of compulsive consumption. Clinically relevant doses of GSK1521498 (2, 5, and 10 mg) following once‐daily administration for 10 days, were well tolerated with no clinically relevant changes in vital signs, chemistry, or hematologic parameters and with a favorable neuropsychiatric profile. Following oral administration, median first time to reach maximum observed plasma concentration for GSK1521498 occurred 2 to 5 hours after dosing, with individual values ranging from 1 to 8 hours. Systemic exposure to GSK1521498 (area under the curve [0–∞] and maximum observed plasma concentration) increased in a slightly greater‐than‐dose‐proportional manner, and steady‐state plasma levels were reached within approximately 7 days. The secondary pharmacodynamic effects of GSK1521498 on cognition and pain threshold and tolerance were dose related, with mild to moderate impairments in measures of attention and reductions of pressure pain threshold and tolerance at the highest dose. These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498.
- 1 October 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (10) , 1456-1467
Multiple‐Dose Safety, Pharmacokinetics, and Pharmacodynamics of the μ‐Opioid Receptor Inverse Agonist GSK1521498
The endogenous opioid system and μ‐opioid receptors in particular have been demonstrated to play a fundamental role in hedonic and motivational behaviors reinforced by rewards. In healthy participants, the authors examined the multiple‐dose safety, pharmacokinetic, and secondary pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being developed for treatment of disorders of compulsive consumption. Clinically relevant doses of GSK1521498 (2, 5, and 10 mg) following once‐daily administration for 10 days, were well tolerated with no clinically relevant changes in vital signs, chemistry, or hematologic parameters and with a favorable neuropsychiatric profile. Following oral administration, median first time to reach maximum observed plasma concentration for GSK1521498 occurred 2 to 5 hours after dosing, with individual values ranging from 1 to 8 hours. Systemic exposure to GSK1521498 (area under the curve [0–∞] and maximum observed plasma concentration) increased in a slightly greater‐than‐dose‐proportional manner, and steady‐state plasma levels were reached within approximately 7 days. The secondary pharmacodynamic effects of GSK1521498 on cognition and pain threshold and tolerance were dose related, with mild to moderate impairments in measures of attention and reductions of pressure pain threshold and tolerance at the highest dose. These findings provide encouraging safety, tolerability, and pharmacokinetic data in support of the continued clinical development of GSK1521498.
- 3 July 2012
- Published by Springer Nature in Psychopharmacology
- Vol. 224 (4) , 501-509
Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
Translational research implicates the mu opioid neurochemical system in hedonic processing, but its role in dissociable high-level cognitive functions is not well understood. Binge-eating represents a useful model of ‘behavioural addiction’ for exploring this issue. The aim of this study was to objectively assess the cognitive effects of a mu opioid receptor antagonist in obese individuals with binge-eating symptoms. Adults with moderate to severe binge-eating and body mass index ≥30 kg/m2 received 4 weeks of treatment with a mu opioid receptor antagonist (GSK1521498) 2 or 5 mg per day, or placebo, in a double-blind randomised parallel design. Neuropsychological assessment was undertaken at baseline and endpoint to quantify processing bias for food stimuli (visual dot probe with 500- and 2,000-ms stimulus presentations and food Stroop tasks) and other distinct cognitive functions (N-back working memory, sustained attention, and power of attention tasks). GSK1521498 5 mg/day significantly reduced attentional bias for food cues on the visual dot probe task versus placebo (p = 0.042), with no effects detected on other cognitive tasks (all p > 0.10). The effect on attentional bias was limited to the longer stimulus duration condition in the higher dose cohort alone. These findings support a central role for mu opioid receptors in aspects of attentional processing of food cues but militate against the notion of major modulatory influences of mu opioid receptors in working memory and sustained attention. The findings have implications for novel therapeutic directions and suggest that the role of different opioid receptors in cognition merits further research.
- 3 July 2012
- Published by Springer Nature in Psychopharmacology
- Vol. 224 (4) , 501-509
Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals
Translational research implicates the mu opioid neurochemical system in hedonic processing, but its role in dissociable high-level cognitive functions is not well understood. Binge-eating represents a useful model of ‘behavioural addiction’ for exploring this issue. The aim of this study was to objectively assess the cognitive effects of a mu opioid receptor antagonist in obese individuals with binge-eating symptoms. Adults with moderate to severe binge-eating and body mass index ≥30 kg/m2 received 4 weeks of treatment with a mu opioid receptor antagonist (GSK1521498) 2 or 5 mg per day, or placebo, in a double-blind randomised parallel design. Neuropsychological assessment was undertaken at baseline and endpoint to quantify processing bias for food stimuli (visual dot probe with 500- and 2,000-ms stimulus presentations and food Stroop tasks) and other distinct cognitive functions (N-back working memory, sustained attention, and power of attention tasks). GSK1521498 5 mg/day significantly reduced attentional bias for food cues on the visual dot probe task versus placebo (p = 0.042), with no effects detected on other cognitive tasks (all p > 0.10). The effect on attentional bias was limited to the longer stimulus duration condition in the higher dose cohort alone. These findings support a central role for mu opioid receptors in aspects of attentional processing of food cues but militate against the notion of major modulatory influences of mu opioid receptors in working memory and sustained attention. The findings have implications for novel therapeutic directions and suggest that the role of different opioid receptors in cognition merits further research.
- 1 April 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (4) , 464-474
Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist
Endogenous opioids and μ‐opioid receptors have been linked to hedonic and rewarding aspects of palatable food intake. The authors examined the safety, pharmacokinetic, and pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being investigated primarily for the treatment of overeating behavior in obesity. In healthy participants, GSK1521498 oral solution and capsule formulations were well tolerated up to a dose of 100 mg. After single doses (10–150 mg), the maximum concentration (Cmax) and area under the curve (AUC) in plasma increased in a dose‐proportional manner. GSK1521498 selectively reduced sensory hedonic ratings of high‐sugar and high‐fat dairy products and caloric intake of high‐fat/high‐sucrose snack foods. These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption.
- 1 April 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (4) , 464-474
Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist
Endogenous opioids and μ‐opioid receptors have been linked to hedonic and rewarding aspects of palatable food intake. The authors examined the safety, pharmacokinetic, and pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being investigated primarily for the treatment of overeating behavior in obesity. In healthy participants, GSK1521498 oral solution and capsule formulations were well tolerated up to a dose of 100 mg. After single doses (10–150 mg), the maximum concentration (Cmax) and area under the curve (AUC) in plasma increased in a dose‐proportional manner. GSK1521498 selectively reduced sensory hedonic ratings of high‐sugar and high‐fat dairy products and caloric intake of high‐fat/high‐sucrose snack foods. These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption.
- Open Access
- 12 July 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (02) , 149-161
The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
The mesolimbic dopamine system plays a critical role in the reinforcing effects of rewards. Evidence from pre-clinical studies suggests that D3 recep
- 12 July 2011
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (02) , 149-161
Open AccessThe effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
The mesolimbic dopamine system plays a critical role in the reinforcing effects of rewards. Evidence from pre-clinical studies suggests that D3 recep
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S78
Differentiation of the Mu-opioid ligand GSK1521498 from naltrexone using [11C]carfentanil PET and fMRI
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S78
Differentiation of the Mu-opioid ligand GSK1521498 from naltrexone using [11C]carfentanil PET and fMRI
- Open Access
- 12 May 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 12 (07) , 995-1008
From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour
Endogenous opioids and µ-opioid receptors (MORs) have long been implicated in the mechanism of appetite control and, in particular, hedonic processes
- 12 May 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 12 (07) , 995-1008
Open AccessFrom taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour
Endogenous opioids and µ-opioid receptors (MORs) have long been implicated in the mechanism of appetite control and, in particular, hedonic processes